We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Final pooled analysis evaluates efficacy and safety of rozanolixizumab in generalized myasthenia gravis, indicating potential benefits.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: